

**Network based meta-analysis prediction of microenvironmental relays  
involved in stemness of human embryonic stem cells**

Authors: Virginie Mournetas<sup>1,2</sup>, Quentin M. Nunes<sup>2,3</sup>, Patricia A. Murray<sup>1</sup>, Christopher M. Sanderson<sup>1</sup>, David G. Fernig<sup>2</sup>

Affiliations: <sup>1</sup> Department of Cellular and Molecular Physiology, Institute of Translational Medicine, <sup>2</sup> Department of Biochemistry, Institute of Integrative Biology, <sup>3</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Institute of Translational Medicine, University of Liverpool, L697ZB Liverpool, United Kingdom

Corresponding authors:

Virginie Mournetas, Stem Cell Group, Department of Cellular and Molecular Physiology, Institute of Translational Medicine, Faculty of Health and Life Sciences, University of Liverpool, Sherrington Building (Nuffield Wing), 2nd Floor, Ashton Street, L69 3GE Liverpool, United Kingdom

E-mail: vmournet@liv.ac.uk

David G. Fernig, Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Biosciences Building, Crown Street, L69 7ZB Liverpool, United Kingdom

E-mail: dgfernig@liv.ac.uk

Tel. +44 (0)151 795 4471

## Abstract

**Background.** Human embryonic stem cells (hESCs) are pluripotent cells derived from the inner cell mass of *in vitro* fertilised blastocysts, which can either be maintained in an undifferentiated state or committed into lineages under determined culture conditions. These cells offer great potential for regenerative medicine, but at present, little is known about the mechanisms that regulate hESC stemness; in particular, the role of cell-cell and cell-extracellular matrix interactions remain relatively unexplored.

**Methods and results.** In this study we have performed an *in silico* analysis of cell-microenvironment interactions to identify novel proteins that may be responsible for the maintenance of hESC stemness. A hESC transcriptome of 8,934 mRNAs was assembled using a meta-analysis approach combining the analysis of microarrays and the use of databases for annotation. The STRING database was utilised to construct a protein-protein interaction network focused on extracellular and transcription factor components contained within the assembled transcriptome. This interactome was structurally studied and filtered to identify a short list of 92 candidate proteins, which may regulate hESC stemness.

**Conclusion.** We hypothesise that this list of proteins, either connecting extracellular components with transcriptional networks, or with hub or bottleneck properties, may contain proteins likely to be involved in determining stemness.

## Introduction

Human embryonic stem cells (hESCs) are pluripotent cells present in the inner cell mass of the blastocyst (Pera et al. 2000). They give rise *in vivo* to the three germ layers (ectoderm, endoderm and mesoderm), and, therefore, have the ability to generate all tissues within the body. These cells can also be derived *in vitro* (Thomson et al. 1998), maintaining an ability to either self-renew or differentiate (Keller 2005). Human ESCs are a fundamental tool for understanding human embryonic development and constituent mechanisms of differentiation (Keller 2005). Moreover, they represent a potentially powerful tool in drug screening (Jensen et al. 2009) and regenerative medicine (Aznar & Gomez 2012; Keller 2005; Wobus & Boheler 2005). However, in order to mobilise the potential of hESCs, it is necessary to understand the molecular determinants of self-renewal and differentiation.

The core transcriptional network regulating pluripotency (Babaie et al. 2007; Boyer et al. 2005; Chavez et al. 2009; Marson et al. 2008; Rodda et al. 2005), is composed of three transcription factors: octamer-binding protein 4 (OCT4) (Hay et al. 2004), sex determining region Y-box 2 (SOX2) (Fong et al. 2008) and NANOG (Hyslop et al. 2005; Zaehres et al. 2005). Interestingly, although these transcription factors clearly drive pluripotency (Li et al. 2009; Takahashi et al. 2007), their expression is not restricted to hESCs (Atlasi et al. 2008; Leis et al. 2012; Liedtke et al. 2007; Pierantozzi et al. 2011; Zangrossi et al. 2007). Thus, stemness must in part depend on other hESC specific characteristics, such as the context of expression of these three transcription factors. Protein-protein interaction networks may provide a valuable insight into this hESC specific context (Boyer et al. 2005; Muller et al. 2008). Proteins of the cell microenvironment may also be an important part of this network (Evseenko et al. 2009; Stelling et al. 2013; Sun et al. 2012), since this is the niche where cell-cell and cell-extracellular matrix (ECM) interactions occur, allowing selective cell communication. Indeed, it was through the addition of ECM proteins and growth factors that

xeno-free culture conditions for hESCs were defined (Melkoumian et al. 2010; Rodin et al. 2010). These methods have facilitated investigation of the roles that extracellular molecules, such as heparan sulfate (HS) (Stelling et al. 2013), fibroblast growth factor (FGF)-2 (Eiselleova et al. 2009; Greber et al. 2010) and activin A (Xiao et al. 2006) play in hESC self-renewal and differentiation. However, such factors have not always been linked to specific transcriptional networks and many of the defined medium formulations do not completely sustain pluripotency (Baxter et al. 2009; Ludwig et al. 2006). Therefore, other factors involved in the maintenance of stemness must be missing. One key factor could be a wider link between ECM interactions and transcriptional networks, thereby establishing important relay mechanisms between endogenous and exogenous stemness regulators.

Data from large-scale transcriptomic and proteomic studies (Koh et al. 2012) facilitate the construction of large biological networks in which nodes and edges represent molecules and interactions respectively. Studying the topological properties of these networks may enable the elaboration of novel hypotheses. For instance, it has been shown that hubs, which are highly connected nodes within a network, are more likely to be important proteins in a protein-protein interaction network (Jeong et al. 2001), as well as bottlenecks, which are nodes with a high betweenness centrality, meaning many shortest paths within the network pass through them (Yu et al. 2007).

To gain a more global insight into the potential contribution of the cell-microenvironment to stemness, we employed an *in silico* systems-level approach where a meta-analysis of dozens of microarrays was performed to establish a stringent yet more representative hESC transcriptome. Transcripts of transcriptional and extracellular proteins were used to build a putative interactome or protein-protein interaction network. The organisation of this network was then analysed to identify extracellular proteins with hub or bottleneck properties, which

may be involved in determining stemness, as well as proteins connecting the extracellular factors to transcription.

## Materials and methods

### Establishing hESC and hESC-derived transcriptomes

The microarray datasets used to establish a high coverage hESC transcriptome were raw data (.CEL image files) of single channel Human Genome U133 Plus 2.0 Affymetrix microarrays downloaded from the ArrayExpress public database (Parkinson et al. 2007). Probe intensity extraction and normalisation procedures were performed with BRB-ArrayTools 4.3.0 beta 1 (Simon et al. 2007) using default median array values (selected by BRB-ArrayTools 4.3.0 beta 1) as reference. The minimum required fold change was 1.5. If less than 20% of the expression values met this value, the gene was excluded. Each individual dataset was first analysed using the three available algorithms: Robust Multi-array Analysis (RMA) (Irizarry et al. 2003), GC-RMA (Wu et al. 2004) and Micro Array Suite 5.0 (MAS5.0) (Hubbell et al. 2002). The three lists of expressed genes were either combined to create a total list containing all expressed genes, or compared to create an intersection list containing only overlapping genes. For the hESC datasets, when the intersection list contained at least 50% of the genes of the total list, the dataset was used to perform a meta-analysis to establish the hESC transcriptome. Thus, all hESC datasets matching this criterion were grouped to be analysed together and generate the final intersection list used as the hESC transcriptome for further analysis (Fig. S1). For the hESC-derived cell datasets, if the intersection list contained at least 50% of the genes of the total list, the full transcriptome (fibroblasts and endothelial cells) was used for transcriptomic comparisons; otherwise the datasets were combined to build the final intersection list and form the hESC-derived cell transcriptome, which was used for transcriptomic comparisons (Fig. S1). The identifiers were EntrezGene IDs and Official Gene

Symbol identifiers. The identifier conversion was done with the database for annotation, visualization and integrated discovery (DAVID) 6.7 (Huang da et al. 2009a; Huang da et al. 2009b).

### **Selection of extracellular and transcription related sub-transcriptomes**

The extracellular (EC) and the transcription factor related (TF) components of the transcriptomes were extracted using the Gene Ontology (GO) database (Ashburner et al. 2000). The terms used were: GO:0005576 (extracellular region) and GO:0009986 (cell surface) for the EC component; GO:0005667 (transcription factor complex), GO:0008134 (transcription factor binding), GO:0000988 (protein binding transcription factor activity) and GO:0001071 (nucleic acid binding transcription factor activity) for the TF component. Genes involved in biological processes (e.g. cell cycle (GO:0007049), cell adhesion (GO:0007155), cell communication (GO:0007154), cell junction (GO:0030054) and cytoskeleton organization (GO:0007010)) were also highlighted.

By using a published list of HS binding proteins (Ori et al. 2011), the EC component was divided into two distinct groups: genes coding for HS binding proteins and those coding for non-HS binding proteins.

The hESC transcriptome was compared with the three different hESC-derived cell transcriptomes to establish which mRNAs were only expressed in hESC (the specific part) and which ones were expressed in all analysed transcriptomes (the common part).

### **Construction and analysis of putative interactomes**

Putative interactomes were built with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 9.0 database (Szklarczyk et al. 2011) using interaction data from experiments and databases only. A stringent interaction confidence of 0.7 was imposed, to ensure a higher probability that the predicted links exist (Szklarczyk et al. 2011).

### ***Analysis of network structure***

Cytoscape 2.8.0 software (Shannon et al. 2003) and associated plug-ins were used to visualise and analyse protein-protein interaction networks. Randomised networks were created by the RandomNetworks v1.0 plug-in from the real protein-protein interaction networks. Therefore, each random network had the same number of nodes  $N$  and edges  $L$  as its corresponding real network. Network topological parameters, such as connected components, average degree  $\langle k \rangle$ , degree distribution  $P(k)$ , average clustering coefficient  $\langle C \rangle$ , clustering coefficient distribution  $C(k)$  and characteristic path length  $\langle l \rangle$ , were computed with the NetworkAnalyser plug-in. Statistical analysis was performed using IBM SPSS Statistics 21 software.

### ***Enrichments analysis of interactome components***

Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa & Goto 2000) pathway and GO Biological Processes term enrichments were processed using DAVID 6.7 (Huang da et al. 2009a; Huang da et al. 2009b) for the analysis of transcriptome subsets. Terms were recorded when the EASE score was  $\leq 0.1$  and considered significantly enriched when the false discovery rate was  $\leq 0.05$ . Enrichment was calculated through two different ways: the ratio of the ratio of proteins belonging to the term in the analysed list and the ratio of proteins belonging to the term in *Homo sapiens*, or hESCs.

### ***Selection of candidate proteins***

Proteins with a degree  $k$  in the top 20% were considered as hubs, while proteins with a betweenness in the top 20% were considered as bottlenecks (Yu et al. 2007). The EC/TF and specific/common interfaces were established from the hESC sub-interactome, constructed with STRING data (edge confidence of 0.7) and containing EC and TF components only. To

be part of the EC/TF interface network, an EC node had to be connected to a least one TF node and *vice-versa*. Similarly, to be part of the specific/common interface, a specific node had to be connected to a least one common node and *vice-versa*. In this complete (ALL\_EC+TF) list of candidate proteins composed of the two interfaces, hubs and bottlenecks, only the EC nodes from the specific and common parts were kept to establish the final (C+S\_EC) short list of candidate proteins (Fig. S2). The KEGG pathway and GO Biological Processes term enrichments were processed as previously. Statistical analysis was performed using IBM SPSS Statistics 21 software and presented as mean  $\pm$  SEM.

## Results

### The hESC transcriptome

To discover new regulators of hESC pluripotency, 24 hESC microarrays were analysed from four different datasets (Table 1). A total of 8,934 genes were found to be expressed, which constitute the high coverage hESC transcriptome (Table S1). To establish hESC specific expression profiles, three different early hESC-derived cell transcriptomes were extracted from analogous fibroblast (5,086 mRNAs), endothelial cells (5,522 mRNAs) or mixed hESC-derived cells (10,730 mRNAs, Table 1 and Table S1).


Cell type	Access Number	Linked publication	Number of microarrays	RMA	GC-RMA	MAS5.0	TOTAL	INTERSECTION
hESCs	E-GEOD-6561	(Baker et al. 2007)	4	9672	8680	9822	11930	7088
hESCs	E-GEOD-15148	(Yu et al. 2009)	10	8798	10554	10293	12467	7395
hESCs	E-GEOD-18265	/	5	9602	11325	10966	13499	7791
hESCs	E-GEOD-26672	(Hu et al. 2011)	5	9656	11285	10843	12790	8235
<b>hESCs</b>	<b>Mix1</b>	<b>/</b>	<b>24</b>	<b>11001</b>	<b>12173</b>	<b>11546</b>	<b>14043</b>	<b>8934</b>
Embryoid bodies	E-GEOD-9196	(Lu et al. 2007)	9	5142	6308	6667	8935	3576
Blast cells			9	4142	5866	6731	8617	3175
<b>Fibroblasts</b>	<b>E-GEOD-9832</b>	<b>(Park et al. 2008)</b>	<b>3</b>	<b>6471</b>	<b>7510</b>	<b>8072</b>	<b>9795</b>	<b>5086</b>
Neural progenitors	E-GEOD-9940	/	12	6939	8432	7309	11517	3944
Embryoid bodies			3	1356	2485	5009	5812	942
Hepatic cells	E-GEOD-14897	(Si-Tayeb et al. 2010)	3	1669	2659	4017	4864	1299
<b>Endothelial cells</b>	<b>E-GEOD-19735</b>	<b>/</b>	<b>4</b>	<b>7166</b>	<b>9237</b>	<b>8448</b>	<b>11085</b>	<b>5522</b>
Embryoid bodies			2	704	1832	1156	2079	583
Mesenchymal progenitors	E-GEOD-21668	(Evseenko et al. 2010)	3	861	1482	2543	3087	638
<b>Differentiated cells</b>	<b>Mix2</b>	<b>/</b>	<b>48</b>	<b>16174</b>	<b>14172</b>	<b>12134</b>	<b>17458</b>	<b>10730</b>



# Table 1 - Microarray datasets analysis

The access number (second column) gives access to the dataset in ArrayExpress database. Cell types (first column), publications linked to the dataset (when available, third column) and the number of microarrays used per analysis (fourth column) are specified. Expressed gene lists for each algorithm (RMA, GC-RMA and MAS5.0) as the total and intersection lists are presented. Four hESC datasets (E-GEOD-6561, -15148, -18265 and -26672) have been used to build mix1. Six hESC-derived cell datasets (E-GEOD-9196, -9832, -9940, -14897, -19735 and -21668) have been used to build mix2. Datasets in bold represent the final transcriptomes used for further analysis: mix1 for hESCs, E-GEOD-9832 for the fibroblasts, E-GEOD-19735 for the endothelial cells and mix2 for the mixture of hESC-derived cells.

The mRNAs specifically expressed by the hESCs (1,010 mRNAs) and those common to hESCs and hESC-derived cells (1,933 mRNAs) were identified by comparing the hESC transcriptome with the hESC-derived transcriptomes (Fig. 1A). Gene Ontology (GO) annotation database (Ashburner et al. 2000) was then used to identify the hESC transcription factor (TF) related (721 mRNAs) and extracellular (EC) transcripts. In this last set of mRNAs, a distinction between transcripts coding for HS binding proteins (191 mRNAs) and non-binding proteins (576 mRNAs, Fig. 1B and Table S1) was enabled by a published list of HS binding proteins (Ori et al. 2011).



## Figure 1 - Overlaps of transcriptomes and sub-transcriptomes

A) Main overlaps of hESC and hESC-derived cell transcriptomes. Grey: hESC transcriptome; Blue: endothelial cell transcriptome; Red: fibroblast transcriptome; Green: mixture of hESC-derived cell transcriptome. B) The overlaps of hESC sub-transcriptomes. The hESC transcriptome is composed of 8,934 mRNAs in total with a hESC-specific part (1,010 mRNAs, brown part), a common part (1,933 mRNAs, blue part) shared with the hESC-derived cells, and the rest of the mRNAs (grey). Sub-transcriptomes can be highlighted: the HS binding proteins part (191 mRNAs, specific in red and common in pink); the extracellular part (EC) without HS binding proteins (576 mRNAs, specific in orange and common in purple); the transcription factor related part (TF, 721 mRNAs, specific in yellow and common in light blue).

Transcriptome analysis showed that genes known to be involved in stemness were represented in this hESC transcriptome, such as POU class 5 homeobox 1 (POU5F1, which encodes OCT4 protein) (Nichols et al. 1998) and SOX2 (Avilion et al. 2003). As expected, some of these were in the hESC specific sub-set, such as the telomerase reverse transcriptase (TERT) (Yang et al. 2008) and growth differentiation factor 3 (GDF3) (Levine & Brivanlou 2006) (Table 2A). Interestingly, NANOG (Chambers et al. 2003) was not present here. Some germ layer markers were also found in the hESC transcriptome, but they were never specific (Table 2B). Lastly, many common additions to cell culture medium, which have been observed to facilitate hESC growth *in vitro*, such as FGF2 (Eiselleova et al. 2009; Vallier et al. 2005) and activin A (Xiao et al. 2006) were also present (Table 2C).

	Marker/Family	Acronym	Name	Transcriptome	GO term
A	Embryonic stem cell	PTEN	phosphatase and tensin homolog	hESC (COMMON)	CS/CA/CC/Cco
		TERT	telomerase reverse transcriptase	hESC (SPECIFIC)	
		GDF3	growth differentiation factor 3	hESC (SPECIFIC)	EC non-HS
		NODAL	nodal homolog (mouse)	hESC (SPECIFIC)	CCo/EC non-HS
		ZIC3	Zic family member 3	hESC, Mix	TF
		SOX2	SRY (sex determining region Y)-box 2	hESC, Mix	CC/CCo/TF
		POU5F1	POU class 5 homeobox 1	hESC, Mix	CCo/TF
B	Ectoderm	NEFH	neurofilament, heavy polypeptide	hESC (COMMON)	CS
		TUBB3	tubulin, beta 3 class III	hESC, Mix	CCo
	Endoderm	KRT19	keratin 19	hESC (COMMON)	CS
		SOX7	SRY (sex determining region Y)-box 7	hESC, Endo, Mix	CCo/TF
	Mesoderm	KDR	kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGFR)	hESC, Mix	CA/CCo/HS
		PDGFRA	platelet-derived growth factor receptor, alpha polypeptide	hESC (COMMON)	CS/CA/CCo
C	Fibronectin	VIM	Vimentin	hESC (COMMON)	CS
		FN1	fibronectin 1	hESC (COMMON)	CA/HS
		ITGA5	integrin, alpha 5 (fibronectin receptor, alpha polypeptide)	hESC, Mix	CA/CCo/J/HS
	Fibroblast Growth Factor	ITGB1	integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)	hESC, Endo, Mix	CS/CA/CC/CCo/J/HS
		FGF2	Fibroblast growth factor 2	hESC (COMMON)	CC/CCo/HS/TF
		FGFR1	Fibroblast growth factor receptor 1	hESC (COMMON)	CC/CCo/HS
		FGFR2	Fibroblast growth factor receptor 2	hESC, Endo, Mix	CC/CCo/HS
		FGFR3	fibroblast growth factor receptor 3	hESC, Endo, Mix	CCo/J/HS
		FGFR4	Fibroblast growth factor receptor 4	hESC (SPECIFIC)	CCo/J/HS
	Activin A	ACVR1B	activin A receptor, type IB (ALK4)	hESC (COMMON)	CC/CCo/EC non-HS
		ACVR1C	activin A receptor, type IC	hESC (SPECIFIC)	CCo
		ACVR2A	activin A receptor, type IIA	hESC, F, Mix	CCo
		ACVR2B	activin A receptor, type IIB	hESC, Endo, Mix	CCo/EC non-HS
		INHBA	inhibin, beta A / Activin A	hESC (COMMON)	CC/CCo/HS

**Table 2 - Transcriptomes and literature comparisons, a selection of markers**


'Transcriptome' column: transcriptome(s) or sub-transcriptome containing the mRNAs (Endo: endothelial cell; F: fibroblast; Mix: mixture of hESC-derived cells). GO term column: GO terms found during the GO extraction (CA: cell adhesion; CC: cell cycle; CCo: cell communication; CS: cytoskeleton organisation; J: cell junction; EC: extracellular part; HS: heparan sulfate binding proteins; TF: transcription factor related part). A) Signalling molecules required for pluripotency/self-renewal; B) Germ layer markers and C) Molecules related to culture medium of hESCs.

## Putative extracellular/transcriptional interactomes

As the aim of this study was to learn more about the potential importance of functional links between cell/cell-matrix interactions and transcription, putative protein-protein interaction networks containing only transcriptional and extracellular components (EC+TF) were established by means of the STRING database (Szklarczyk et al. 2011) using transcriptional expression data as a proxy for protein expression profiles. Two interactomes were built: one (called ALL) containing all identified EC+TF proteins, composed of 702 nodes and 3,201 edges (Data S1A), and one (called C+S) containing only those transcripts/proteins that were either specific to hESCs or common to hESCs and hESC-derived cells, comprising 209 nodes and 371 edges (Data S1B).

The average clustering coefficient  $\langle C \rangle$  (indicating the network cohesiveness) was closer to zero for all randomised networks compared to both ALL and C+S interactomes, implying a significantly higher occurrence of clusters in these selected networks (Fig. 2A).

As observed in previous protein-protein interaction network studies (Albert et al. 2000; Jeong et al. 2001), both selected networks (ALL and C+S) and randomised networks exhibit a scale-free structure, where the degree distribution  $P(k)$  follows a power-law  $P(k) \sim k^{-\gamma}$ , involving the presence of hubs (Fig. 2B and Table S2), and the clustering coefficient distribution  $C(k)$  is independent of  $k$  meaning there is no inherent presence of modules unlike hierarchical networks, even if there was a tendency to be hierarchical ( $C(k) \sim k^{-\beta}$ ) compared to the randomised versions (Fig. 2C).



**Figure 2 - General network parameters of EC+TF putative interactomes**

A) The average clustering coefficient  $\langle C \rangle$  of real networks and their corresponding average randomised networks with SEM bars (One sample t-test,  $n=5$ ,  $p\text{-value} < 0.001$ ). B) The node degree distribution  $P(k)$  and C) the clustering coefficient distribution  $C(k)$  (C: common part; S: specific part; R: random; EC: extracellular part; TF: transcription factor related part).

These results demonstrate that the EC+TF putative protein-protein interaction networks were suitable for further analysis.


## Enrichment analysis

GO Biological Processes term and KEGG pathway enrichments were used to determine if the EC+TF putative interactomes contained significantly enriched sub-sets of proteins. As expected, terms related to EC (*extracellular matrix organization*), and TF (*transcription, DNA templated*) appeared. More interestingly, terms relating to development (*embryonic development*) and pathways already known to be involved in hESC stemness maintenance (transforming growth factor (TGF)- $\beta$  (James et al. 2005) or wingless-type MMTV integration site family (Wnt) (Sato et al. 2004)) and differentiation (bone morphogenic protein (BMP) signalling (Xu et al. 2005)) were also identified. KEGG *Pathways in cancer* as well as GO terms of cell differentiation, cell adhesion, cell communication and cell proliferation were represented too (Fig. 3 and Table S3A).

256 Fewer terms were found to be significantly enriched when only the common and specific  
257 parts (from ALL to C+S) were analysed. However, when they were found significant, the  
258 vast majority was more enriched, except the terms related to TF (Table S3A). *Nuclear-*  
259 *transcribed mRNA catabolic process* (representing 56% of ALL and 48% of C+S) and  
260 *multicellular organismal development* (representing 47% of ALL and 54% of C+S) were the  
261 most represented non-related terms (Table S3A).

262 Interestingly, *regulation of cellular component movement* was well enriched with fold  
263 changes in ALL of 5.8 (*Homo sapiens* as background)/4.6 (hESC as background) and in C+S  
264 of 9.4 (*Homo sapiens* as background)/7.4 (hESC as background). 28%/51% of the proteins  
265 belonging to this term in *Homo sapiens*/hESC were represented in ALL and 17%/31% in  
266 C+S (Table S3A).

267 These data show that the EC+TF putative interactomes, both ALL and C+S, still contained  
268 the sub-sets of proteins involved in development, cell differentiation, cell adhesion and cell  
269 communication.



270

271 **Figure 3 – GO/KEGG analyses of EC+TF putative interactomes**

272 A) GO Biological Processes term enrichment (against *Homo sapiens*), in fold change. B) Percentage of the total  
 273 number of proteins in *Homo sapiens* related to GO Biological Processes that are present in ALL and C+S  
 274 putative interactomes (C: common part; S: specific part).


## Novel proteins potentially associated with stemness

The final list of potential stemness proteins was established from ALL, the EC+TF putative protein-protein interaction network. This list (called ALL\_EC+TF) was composed of nodes with hub or bottleneck features, as well as nodes within the specific/common and EC/TF interfaces (Fig. S2). Hubs are thought to be functionally important due to their high number of interactions, while bottlenecks form links between different processes. 58% of the bottlenecks in the ALL network were also hubs. The specific/common interface reflects the links between the more general cell functions and those specific to hESCs. The EC/TF interface represents points of communication between the genome and the cell's environment, including other cells. The ALL\_EC+TF contained 387 candidates (49% EC and 55% TF) with 29 specific (8%) and 126 common (33%) nodes. The key transcription factors OCT4 and SOX2 were present as hubs and part of the EC/TF interface (Table S4A).

Considering GO set (TF, EC) enrichment with regards to proteins belonging to common or specific parts of the transcriptome, the specific sub-set was enriched in non-HS binding EC proteins (1.7-fold change), whereas the common sub-set was enriched in HS binding proteins (1.6-fold change) (Fig. 4A). In addition the common sub-set was found to be enriched in both hubs (1.3-fold change) and bottlenecks (1.6-fold change) (Fig. 4B). Finally, hubs were enriched in TF (1.4-fold change) and bottlenecks in HS binding proteins (1.3-fold change, Fig. 4B).

To assess the validity of the candidate prediction, a random ALL\_EC+TF list was established the same way using a randomised version of the EC+TF putative interactome (Table S4B).





**Figure 4 - Comparative enrichment trends within the candidate protein list**

A) Enrichments in specific, common and other parts with HS, EC non-HS and TF. B) Enrichments in HS, EC non-HS and TF parts with EC/TF interface, C/S interface, hubs and bottlenecks (C: common part; S: specific part; EC: extracellular part; HS: heparan sulfate binding proteins; TF: transcription factor related part).

The hub sub-set was identical in both real and random versions of the candidate list due to the way the randomised network was generated. However, the bottleneck sub-set in the real list had proteins with significantly higher betweenness centrality ( $7,456 \pm 835$ , paired sample test,  $n=134$ ,  $p\text{-value} < 0.001$ ) than the one in the random list ( $0.0108 \pm 0.0005$ ). Moreover, the random list with 581 proteins retained 83% of the original EC+TF putative interactome against 55% for the real list. The comparison between the real list of candidates and its random version showed that the filtering process was meaningful.

Three shortened lists were generated from ALL\_EC+TF list to decrease the number of candidates by either keeping only EC proteins (ALL\_EC, 188 proteins, Table S4C) or/and C+S proteins (C+S\_EC+TF, 155 proteins, Table S4D and C+S\_EC, 92 proteins, Table S4E) as described in Fig. S2. 59% of the common proteins in the longest ALL\_EC+TF list and 62% of the specific ones were conserved in the shortest C+S\_EC list. Similarly, 9% of the hubs and 20% of the bottlenecks were kept.



To determine if each list and each sub-set (hubs, bottlenecks and interfaces, as well as specific, common and other proteins from the complete (ALL\_EC+TF) to the shortest (C+S\_EC) list) still contained proteins potentially involved in stemness maintenance, we undertook further GO Biological Processes term and KEGG pathway enrichments (Table S3B-I). Only the sub-set containing the hESC-specific proteins was found without any significant enrichment regarding the analysed terms and pathways (Table S3C). However, the most represented term in both specific sub-sets from the ALL\_EC+TF and ALL\_EC, as well as in the four full lists and in all other sub-sets, was *multicellular organismal development* (Table S3B-I).

Again, terms and pathways related to TF appeared in ALL\_EC+TF and C+S\_EC+TF lists, as well as in all the other sub-sets of these two lists (Table S3B,D-I). These TF terms and pathways were logically lost in the ALL\_EC and C+S\_EC lists and sub-sets.

GO terms related to cell differentiation, cell adhesion, cell communication, cell movement or cell proliferation, and KEGG *pathways of cancer* were still significantly enriched in the four lists and in the vast majority of the analysed sub-sets (Table S3B,D-I).

These data demonstrate that the four lists of candidates, as well as each sub-set of proteins (hubs, bottlenecks, specific/common and EC/TF interfaces) incorporated proteins involved in development and cell communication. Focusing on the EC proteins that were either specific to hESCs or common to hESCs and hESC-derived cells allowed us to reduce the number of candidates to 92 proteins (Table 3 and Table S4E), while insuring that proteins potentially involved in stemness maintenance were retained. Among these proteins, some are already known to be required for maintenance of hESC stemness, either directly, such as NODAL (James et al. 2005; Vallier et al. 2005), FGF2 (Eiselleova et al. 2009; Vallier et al. 2005) and activin A (Xiao et al. 2006), or indirectly through signalling pathways such as TGF- $\beta$  (James

et al. 2005) or Wnt (Sato et al. 2004). Other proteins are also known to play a role in mouse ESC pluripotency, but not yet in hESC, such as the transcription factor 3 (TCF3) (Cole et al. 2008). However, for the majority of candidates, including titin, nothing is known yet about their functions in the context of hESCs.

	Acronym	Name	GO term	Hubs	Bottlenecks	S/C	EC/TF	KEGG pathway
C	ACTN4	actinin, alpha 4	EC non-HS/CS	17				4
	ACVR1B	activin A receptor, type IB (ALK4)	EC non-HS/CC/CCo			X	X	1
	ADM	adrenomedullin	EC non-HS/CCo		4050.8	X	X	0
	BMP2	bone morphogenetic protein 2	HS/CC/CCo		2693.9	X	X	3
	DMD	dystrophin	EC non-HS/CS/CCo			X		0
	FGFR1	Fibroblast growth factor receptor 1	HS/CC/CCo		2634.2	X	X	5
	FN1	fibronectin 1	HS/CA	26	6988.8		X	5
	IL6	Interleukin 6	HS/CCo				X	4
	INHBA	inhibin, beta A / Activin A	HS/CC/CCo			X		2
	ITGA6	integrin, alpha 6 (CD49f)	EC non-HS/CA/CCo/J	40	15218.1		X	6
	ITGAV	integrin, alpha V (vitronectin receptor)	HS/CA/CCo	40	12409.4		X	6
	JAM3	junctional adhesion molecule 3	EC non-HS/CA/CCo/J			X	X	2
	LAMA1	laminin, alpha 1	HS/CA/CCo	15			X	4
	MET	(hepatocyte growth factor receptor	HS/CS/CC/CCo	24	10501.7	X	X	6
	PLAT	plasminogen activator, tissue	HS/CCo		2552.8		X	0
	PLAU	plasminogen activator, urokinase	HS/CA/CCo				X	1
	SERPINE1	serpin peptidase inhibitor, clade E, member 1	HS/CA/CCo	24	10022.8		X	1
	SERPINI1	serpin peptidase inhibitor, clade I, member 1	EC non-HS/CA				X	0
	TGFB2	transforming growth factor, beta 2	HS/CA/CC/CCo	25	10580.8	X	X	6
	THBS1	thrombospondin 1	HS/CA/CC/CCo		2066.0		X	5
	VEGFA	vascular endothelial growth factor A	HS/CA/CCo	16	6817.1		X	6
S	CDH8	cadherin 8, type 2	HS/CA			X	X	0
	FGF4	fibroblast growth factor 4	HS/CA/CCo			X	X	3
	FGFR4	Fibroblast growth factor receptor 4	HS/CCo			X	X	4
	IDE	insulin-degrading enzyme	EC non-HS/CCo			X		0
	INHBE	inhibin, beta E	EC non-HS			X		2
	NODAL	nodal homolog (mouse)	EC non-HS/CCo			X		1
	PLXNB1	plexin B1	EC non-HS/CCo			X		0
	TTN	titin	EC non-HS/CS/CC			X	X	0
	WIF1	WNT inhibitory factor 1	EC non-HS/CCo			X	X	1

**Table 3 - The list of candidates, an overview**

The 'hubs' column gives the degree; the 'bottlenecks' column gives the betweenness; the 'S/C' column indicates if the protein is in the specific/common interface; the 'EC/TF' column indicates if the protein is in the EC/TF interface; the 'KEGG pathway' column indicates the number of pathway involving each protein (GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; C: common part; S: specific part; EC: extracellular part; TF: transcription factor related part; J: cell junction). (see Table S4 for a complete list).

## Discussion

We provide a novel picture of the hESC transcriptome built from a meta-analysis and allowing the *in silico* analysis of a putative hESC protein-protein interaction network. This systems-level approach has been used to identify proteins potentially involved in the maintenance of stemness.

Transcriptomic data provide the most comprehensive insight into variations in cell type or condition specific gene expression profiles. Therefore, data from multiple microarray studies were chosen to generate putative interactomes due to the lack of corresponding comprehensive proteomic profiles. Even if mRNA and protein levels have been suggested to correlate weakly, this correlation may be stronger than anticipated, though this depends on the techniques used to measure mRNA (Jingyi et al. 2014; Pascal et al. 2008; Schwanhauser et al. 2011; Schwanhäusser et al. 2013). Thus, the present study provides a predictive qualitative insight into sub-networks of proteins, which may mediate or maintain human stem cell pluripotency.

The decision to selectively include genes only found by three different algorithms allowed a reduction in the number of false positives in the whole transcriptome, but probably amplified the number of false negatives, which may explain the absence of NANOG. Regarding the specific/common distinction, this pipeline permitted confidence about the common mRNA sub-set, whereas it likely increased the false positive rate in the specific mRNA sub-set, which is still half the common one. However, the use of transcriptomic data from different hESC lines cultured under different conditions highlighted the core transcriptome of these cells.

Not all mRNAs were represented in the putative protein-protein interaction network, probably because coverage of human protein-protein interactions in all databases, including STRING, remains incomplete (De Las Rivas & Fontanillo 2010). High edge stringency limits

373 imposed in this study should minimise inclusion of false positive interactions (De Las Rivas  
374 & Fontanillo 2010), thereby increasing confidence in the relevance and utility of predicted  
375 networks.

376 The scale free nature of the EC+TF putative interactomes, mean that they should exhibit a  
377 high error tolerance thanks to redundancy and a high attack vulnerability, due to the presence  
378 of hubs (Albert et al. 2000).

379 Even incomplete interactomes are very complex structures. In order to focus on the likely  
380 most important proteins within this interactome, four selection criteria were applied, the first  
381 being the selection of hESC hubs. These proteins constitute a small, but often essential part of  
382 the interactome (Awan et al. 2007). For example, deletion of just one hub in yeast is often  
383 lethal (Jeong et al. 2001). The second was the selection of bottlenecks, which link processes  
384 and so permit cross-talk. The third and the fourth criteria involved were that proteins had to  
385 be in the specific/common or EC/TF interfaces. These interfaces are posited to be important,  
386 as they reflect communication links between the nucleus and the extracellular matrix, and  
387 between the specific and common proteins, which ultimately make hESCs different from  
388 other cell types.

389 Interestingly, the GO term related to cell motility regulation was strongly represented in the  
390 candidate lists. Cell movement is a key component of morphogenesis. It is usually  
391 accomplished by three steps (protrusion, adhesion and de-adhesion) where cytoskeleton and  
392 ECM are involved (Ananthakrishnan & Ehrlicher 2007). This may be significant as recent  
393 data indicates that cell motion may be an intrinsic feature of hESCs (Li et al. 2010).

394 *Regulation of cell proliferation* also appeared in our analysis of candidate lists. This may be  
395 significant, as cell proliferation is a key property of hESCs, since these cells are able to  
396 proliferate almost indefinitely *in vitro* (Miura et al. 2004). This capability is sustained by the  
397 EC part with growth factors (Activin A (Baxter et al. 2009) and FGF2 (Xu et al. 2005)) and

398 ECM molecules (fibronectin (Baxter et al. 2009) or laminin (Rodin et al. 2010)), as well as  
399 by the TF part through the Smad signalling pathway (James et al. 2005; Vallier et al. 2005).  
400 Cell proliferation can also be linked to the significant enrichment of cancer pathways in  
401 hESCs. Several links arise between cancer and hESCs, for example, the formation of  
402 teratomas as a test to assess pluripotency.

## 403 **Conclusion**

404 Mechanisms involved in stemness are complex, multi-level and determined by the intrinsic  
405 cell potential, cell/cell and cell/matrix interactions. The meta-analysis of transcriptomic data  
406 in this study has allowed the construction of a hESC putative protein-protein interaction  
407 network from which novel ECM proteins have been identified as potential stemness  
408 regulators.

409 Networks are a snapshot of a dynamic model (Assmus et al. 2006; Peltier & Schaffer 2010).  
410 Notions of attractors (or cell stable stationary states), landscapes formed with valleys  
411 (attractors) and hills (barriers between attractors), and cell state transitions described by  
412 dynamic systems theory will complete this systems biology approach and bring new  
413 hypotheses on hESC behaviour (MacArthur et al. 2008; Macarthur et al. 2009; Peltier &  
414 Schaffer 2010; Roeder & Radtke 2009).

415 **Acknowledgments**

416 All publications based on BRB-ArrayTools analyses will contain the acknowledgment:

417 "Analyses were performed using BRB-ArrayTools developed by Dr Richard Simon and

418 BRB-ArrayTools Development Team."

## References

- Albert R, Jeong H, and Barabasi AL. 2000. Error and attack tolerance of complex networks. *Nature* 406:378-382.
- Ananthakrishnan R, and Ehrlicher A. 2007. The forces behind cell movement. *Int J Biol Sci* 3:303-317.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, and Sherlock G. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* 25:25-29.
- Assmus HE, Herwig R, Cho KH, and Wolkenhauer O. 2006. Dynamics of biological systems: role of systems biology in medical research. *Expert Rev Mol Diagn* 6:891-902.
- Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, and Andrews PW. 2008. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. *Stem Cells* 26:3068-3074.
- Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, and Lovell-Badge R. 2003. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 17:126-140.
- Awan A, Bari H, Yan F, Moksong S, and Yang... S. 2007. Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network. *Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network*.
- Aznar J, and Gomez I. 2012. Possible clinical usefulness of embryonic stem cells. *Rev Clin Esp* 212:403-406.
- Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, Lehrach H, Burdon T, and Adjaye J. 2007. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. *Stem Cells* 25:500-510.
- Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, Heath PR, Holden H, and Andrews PW. 2007. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. *Nat Biotechnol* 25:207-215.
- Baxter MA, Camarasa MV, Bates N, Small F, Murray P, Edgar D, and Kimber SJ. 2009. Analysis of the distinct functions of growth factors and tissue culture substrates necessary for the long-term self-renewal of human embryonic stem cell lines. *Stem Cell Res*.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, and Young RA. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122:947-956.
- Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, and Smith A. 2003. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* 113:643-655.
- Chavez L, Bais AS, Vingron M, Lehrach H, Adjaye J, and Herwig R. 2009. In silico identification of a core regulatory network of OCT4 in human embryonic stem cells using an integrated approach. *BMC Genomics* 10:314.
- Cole MF, Johnstone SE, Newman JJ, Kagey MH, and Young RA. 2008. Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. *Genes Dev* 22:746-755.
- De Las Rivas J, and Fontanillo C. 2010. Protein-protein interactions essentials: key concepts to building and analyzing interactome networks. *PLoS Comput Biol* 6:e1000807.
- Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, Tichy B, Dvorakova D, Pospisilova S, Hampl A, and Dvorak P. 2009. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. *Stem Cells* 27:1847-1857.
- Evseenko D, Schenke-Layland K, Dravid G, Zhu Y, Hao QL, Scholes J, Wang XC, Maclellan WR, and Crooks GM. 2009. Identification of the critical extracellular matrix proteins that promote human embryonic stem cell assembly. *Stem Cells Dev* 18:919-928.
- Evseenko D, Zhu Y, Schenke-Layland K, Kuo J, Latour B, Ge S, Scholes J, Dravid G, Li X, MacLellan WR, and Crooks GM. 2010. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. *Proceedings of the National Academy of Sciences of the United States of America* 107:13742-13747.
- Fong H, Hohenstein KA, and Donovan PJ. 2008. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. *Stem Cells* 26:1931-1938.
- Greber B, Wu G, Bernemann C, Joo JY, Han DW, Ko K, Tapia N, Sabour D, Sternecker J, Tesar P, and Scholer HR. 2010. Conserved and divergent roles of FGF signaling in mouse epiblast stem cells and human embryonic stem cells. *Cell Stem Cell* 6:215-226.
- Hay DC, Sutherland L, Clark J, and Burdon T. 2004. Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. *Stem Cells* 22:225-235.



- 476 Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, Choi KD, Stewart R, Thomson JA, and Slukvin, II. 2011.  
477 Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone  
478 marrow and cord blood mononuclear cells. *Blood* 117:e109-119.
- 479 Huang da W, Sherman BT, and Lempicki RA. 2009a. Bioinformatics enrichment tools: paths toward the  
480 comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 37:1-13.
- 481 Huang da W, Sherman BT, and Lempicki RA. 2009b. Systematic and integrative analysis of large gene lists  
482 using DAVID bioinformatics resources. *Nat Protoc* 4:44-57.
- 483 Hubbell E, Liu WM, and Mei R. 2002. Robust estimators for expression analysis. *Bioinformatics* 18:1585-1592.
- 484 Hyslop L, Stojkovic M, Armstrong L, Walter T, Stojkovic P, Przyborski S, Herbert M, Murdoch A, Strachan T,  
485 and Lako M. 2005. Downregulation of NANOG induces differentiation of human embryonic stem cells  
486 to extraembryonic lineages. *Stem Cells* 23:1035-1043.
- 487 Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, and Speed TP. 2003. Summaries of Affymetrix  
488 GeneChip probe level data. *Nucleic Acids Res* 31:e15.
- 489 James D, Levine AJ, Besser D, and Hemmati-Brivanlou A. 2005. TGFbeta/activin/nodal signaling is necessary  
490 for the maintenance of pluripotency in human embryonic stem cells. *Development* 132:1273-1282.
- 491 Jensen J, Hyllner J, and Bjorquist P. 2009. Human embryonic stem cell technologies and drug discovery. *J Cell*  
492 *Physiol* 219:513-519.
- 493 Jeong H, Mason SP, Barabasi AL, and Oltvai ZN. 2001. Lethality and centrality in protein networks. *Nature*  
494 411:41-42.
- 495 Jingyi JL, Peter JB, and Mark DB. 2014. System wide analyses have underestimated protein abundances and the  
496 importance of transcription in mammals. *PeerJ* 2.
- 497 Kanehisa M, and Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 28:27-30.
- 498 Keller G. 2005. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. *Genes*  
499 *Dev* 19:1129-1155.
- 500 Koh GC, Porras P, Aranda B, Hermjakob H, and Orchard SE. 2012. Analyzing protein-protein interaction  
501 networks. *J Proteome Res* 11:2014-2031.
- 502 Leis O, Eguira A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R,  
503 and Martin AG. 2012. Sox2 expression in breast tumours and activation in breast cancer stem cells.  
504 *Oncogene* 31:1354-1365.
- 505 Levine AJ, and Brivanlou AH. 2006. GDF3, a BMP inhibitor, regulates cell fate in stem cells and early  
506 embryos. *Development* 133:209-216.
- 507 Li L, Wang BH, Wang S, Moalim-Nour L, Mohib K, Lohnes D, and Wang L. 2010. Individual cell movement,  
508 asymmetric colony expansion, rho-associated kinase, and E-cadherin impact the clonogenicity of  
509 human embryonic stem cells. *Biophys J* 98:2442-2451.
- 510 Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, and Ding S. 2009. Generation of rat and  
511 human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors.  
512 *Cell Stem Cell* 4:16-19.
- 513 Liedtke S, Enczmann J, Wacławczyk S, Wernet P, and Kogler G. 2007. Oct4 and its pseudogenes confuse stem  
514 cell research. *Cell Stem Cell* 1:364-366.
- 515 Lu SJ, Hipp JA, Feng Q, Hipp JD, Lanza R, and Atala A. 2007. GeneChip analysis of human embryonic stem  
516 cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes. *Genome biology*  
517 8:R240.
- 518 Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, Frane JL, Crandall LJ, Daigh CA, Conard  
519 KR, Piekarczyk MS, Llanas RA, and Thomson JA. 2006. Derivation of human embryonic stem cells in  
520 defined conditions. *Nat Biotechnol* 24:185-187.
- 521 MacArthur BD, Ma'ayan A, and Lemischka IR. 2008. Toward stem cell systems biology: from molecules to  
522 networks and landscapes. *Cold Spring Harb Symp Quant Biol* 73:211-215.
- 523 MacArthur BD, Ma'ayan A, and Lemischka IR. 2009. Systems biology of stem cell fate and cellular  
524 reprogramming. *Nat Rev Mol Cell Biol* 10:672-681.
- 525 Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK,  
526 Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL, Gupta S, Love J, Hannett N, Sharp PA,  
527 Bartel DP, Jaenisch R, and Young RA. 2008. Connecting microRNA genes to the core transcriptional  
528 regulatory circuitry of embryonic stem cells. *Cell* 134:521-533.
- 529 Melkounian Z, Weber JL, Weber DM, Fadeev AG, Zhou Y, Dolley-Sonneville P, Yang J, Qiu L, Priest CA,  
530 Shogbon C, Martin AW, Nelson J, West P, Beltzer JP, Pal S, and Brandenberger R. 2010. Synthetic  
531 peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human  
532 embryonic stem cells. *Nat Biotechnol* 28:606-610.
- 533 Miura T, Mattson MP, and Rao MS. 2004. Cellular lifespan and senescence signaling in embryonic stem cells.  
534 *Aging Cell* 3:333-343.



- 535 Muller FJ, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C, Park IH, Rao MS, Shamir R, Schwartz PH,  
536 Schmidt NO, and Loring JF. 2008. Regulatory networks define phenotypic classes of human stem cell  
537 lines. *Nature* 455:401-405.
- 538 Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, and Smith A. 1998.  
539 Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor  
540 Oct4. *Cell* 95:379-391.
- 541 Ori A, Wilkinson MC, and Fernig DG. 2011. A systems biology approach for the investigation of the  
542 heparin/heparan sulfate interactome. *J Biol Chem*.
- 543 Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, and Daley GQ. 2008.  
544 Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 451:141-146.
- 545 Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, Farne A, Holloway E,  
546 Kolesnykov N, Lilja P, Lukk M, Mani R, Rayner T, Sharma A, William E, Sarkans U, and Brazma A.  
547 2007. ArrayExpress--a public database of microarray experiments and gene expression profiles.  
548 *Nucleic Acids Res* 35:D747-750.
- 549 Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, and Liu AY.  
550 2008. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster  
551 designation antigens in the prostate. *BMC Genomics* 9:246.
- 552 Peltier J, and Schaffer DV. 2010. Systems biology approaches to understanding stem cell fate choice. *IET Syst*  
553 *Biol* 4:1-11.
- 554 Pera MF, Reubinoff B, and Trounson A. 2000. Human embryonic stem cells. *J Cell Sci* 113 ( Pt 1):5-10.
- 555 Pierantozzi E, Gava B, Manini I, Roviello F, Marotta G, Chiavarelli M, and Sorrentino V. 2011. Pluripotency  
556 regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2.  
557 *Stem Cells Dev* 20:915-923.
- 558 Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, and Robson P. 2005. Transcriptional regulation of  
559 nanog by OCT4 and SOX2. *J Biol Chem* 280:24731-24737.
- 560 Rodin S, Domogatskaya A, Strom S, Hansson EM, Chien KR, Inzunza J, Hovatta O, and Tryggvason K. 2010.  
561 Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. *Nat*  
562 *Biotechnol* 28:611-615.
- 563 Roeder I, and Radtke F. 2009. Stem cell biology meets systems biology. *Development* 136:3525-3530.
- 564 Sato N, Meijer L, Skaltsounis L, Greengard P, and Brivanlou AH. 2004. Maintenance of pluripotency in human  
565 and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-  
566 specific inhibitor. *Nat Med* 10:55-63.
- 567 Schwanhaussner B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, and Selbach M. 2011. Global  
568 quantification of mammalian gene expression control. *Nature* 473:337-342.
- 569 Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, and Selbach M. 2013.  
570 Corrigendum: Global quantification of mammalian gene expression control. *Nature* 495:126-127.
- 571 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, and Ideker T. 2003.  
572 Cytoscape: a software environment for integrated models of biomolecular interaction networks.  
573 *Genome Res* 13:2498-2504.
- 574 Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, and Duncan SA. 2010.  
575 Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells.  
576 *Hepatology* 51:297-305.
- 577 Simon R, Lam A, Li MC, Ngan M, Menenzes S, and Zhao Y. 2007. Analysis of gene expression data using  
578 BRB-ArrayTools. *Cancer Inform* 3:11-17.
- 579 Stelling MP, Lages YM, Tovar AM, Mourao PA, and Rehen SK. 2013. Matrix-bound heparan sulfate is  
580 essential for the growth and pluripotency of human embryonic stem cells. *Glycobiology* 23:337-345.
- 581 Sun Y, Villa-Diaz LG, Lam RH, Chen W, Krebsbach PH, and Fu J. 2012. Mechanics regulates fate decisions of  
582 human embryonic stem cells. *PLoS One* 7:e37178.
- 583 Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguéz P, Doerks T, Stark M, Muller J, Bork  
584 P, Jensen LJ, and von Mering C. 2011. The STRING database in 2011: functional interaction networks  
585 of proteins, globally integrated and scored. *Nucleic Acids Res* 39:D561-568.
- 586 Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, and Yamanaka S. 2007. Induction of  
587 pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131:861-872.
- 588 Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, and Jones JM. 1998.  
589 Embryonic stem cell lines derived from human blastocysts. *Science* 282:1145-1147.
- 590 Vallier L, Alexander M, and Pedersen RA. 2005. Activin/Nodal and FGF pathways cooperate to maintain  
591 pluripotency of human embryonic stem cells. *J Cell Sci* 118:4495-4509.
- 592 Wobus AM, and Boheler KR. 2005. Embryonic stem cells: prospects for developmental biology and cell  
593 therapy. *Physiol Rev* 85:635-678.

- 594 Wu Z, Irizarry R, Gentleman R, Murillo F, and Spencer F. 2004. A Model Based Background Adjustment for  
595 Oligonucleotide Expression Arrays. *bePress*.
- 596 Xiao L, Yuan X, and Sharkis SJ. 2006. Activin A maintains self-renewal and regulates fibroblast growth factor,  
597 Wnt, and bone morphogenic protein pathways in human embryonic stem cells. *Stem Cells* 24:1476-  
598 1486.
- 599 Xu RH, Peck RM, Li DS, Feng X, Ludwig T, and Thomson JA. 2005. Basic FGF and suppression of BMP  
600 signaling sustain undifferentiated proliferation of human ES cells. *Nat Methods* 2:185-190.
- 601 Yang C, Przyborski S, Cooke MJ, Zhang X, Stewart R, Anyfantis G, Atkinson SP, Saretzki G, Armstrong L,  
602 and Lako M. 2008. A key role for telomerase reverse transcriptase unit in modulating human  
603 embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. *Stem Cells* 26:850-  
604 863.
- 605 Yu H, Kim PM, Sprecher E, Trifonov V, and Gerstein M. 2007. The importance of bottlenecks in protein  
606 networks: correlation with gene essentiality and expression dynamics. *PLoS Comput Biol* 3:e59.
- 607 Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin, II, and Thomson JA. 2009. Human induced pluripotent  
608 stem cells free of vector and transgene sequences. *Science* 324:797-801.
- 609 Zaehres H, Lensch MW, Daheron L, Stewart SA, Itskovitz-Eldor J, and Daley GQ. 2005. High-efficiency RNA  
610 interference in human embryonic stem cells. *Stem Cells* 23:299-305.
- 611 Zangrossi S, Marabese M, Brogginini M, Giordano R, D'Erasmus M, Montelatici E, Intini D, Neri A, Pesce M,  
612 Rebulla P, and Lazzari L. 2007. Oct-4 expression in adult human differentiated cells challenges its role  
613 as a pure stem cell marker. *Stem Cells* 25:1675-1680.